Literature DB >> 21494994

The use of TachoSil in children undergoing liver resection with or without segmental liver transplantation.

D Mirza1, A J W Millar, K Sharif, H Vilca-Melendez, M Rela, N Heaton.   

Abstract

INTRODUCTION: Local haemostatic agents are used for the control of surgical haemorrhage when standard techniques are inadequate, but there are few studies of these products in children. PATIENTS AND METHODS: This was a prospective, open-label study in which children (aged 4 weeks to 6 years) undergoing liver resection with or without segmental liver transplantation were treated with TachoSil, a collagen patch coated with a dry layer of human fibrinogen and human thrombin, if minor (i. e., oozing) or moderate bleeding was present after primary haemostatic treatment. Time to haemostasis after TachoSil application was the primary endpoint. Safety was assessed by adverse events (AEs), including post-operative infections, symptoms of graft rejection and re-operations.
RESULTS: Enrolment was stopped early after 16 children had entered the study. 13 children underwent whole liver resection and transplantation and 3 patients underwent segmental resection. Satisfactory haemostasis was achieved in 13 children (81.3%; 95% CI: 61.8-100%) at 3 min and in 1 child at 8 min. Occurrence of AEs was as expected, with most being known complications of the underlying disease, surgical procedure, or use of immunosuppressive medication. No AEs were considered to be related to the use of TachoSil.
CONCLUSIONS: The use of TachoSil for haemostasis after primary haemostatic treatment appears to be safe and effective in children undergoing liver resection. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21494994     DOI: 10.1055/s-0030-1267221

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  5 in total

Review 1.  Clinical applications of naturally derived biopolymer-based scaffolds for regenerative medicine.

Authors:  Whitney L Stoppel; Chiara E Ghezzi; Stephanie L McNamara; Lauren D Black; David L Kaplan
Journal:  Ann Biomed Eng       Date:  2014-12-24       Impact factor: 3.934

2.  Hemostatic Agents in Hepatobiliary and Pancreas Surgery: A Review of the Literature and Critical Evaluation of a Novel Carrier-Bound Fibrin Sealant (TachoSil).

Authors:  K A Simo; E M Hanna; D K Imagawa; D A Iannitti
Journal:  ISRN Surg       Date:  2012-09-13

3.  Comparison of TachoSil and TachoComb in patients undergoing liver resection-a randomized, double-blind, non-inferiority trial.

Authors:  S Kawasaki; H Origasa; V Tetens; M Kobayashi
Journal:  Langenbecks Arch Surg       Date:  2017-04-01       Impact factor: 3.445

4.  PEDIATRIC LIVER TRANSPLANTATION WITH EX-SITU LIVER TRANSECTION AND THE APPLICATION OF THE HUMAN FIBRINOGEN AND THROMBIN SPONGE IN THE WOUND AREA.

Authors:  Fernando Pompeu Piza Vicentine; Adriano Miziara Gonzalez; Ramiro Anthero de Azevedo; Barbara Burza Benini; Marcelo Moura Linhares; Gaspar de Jesus Lopes-Filho; Jose Luiz Martins; Alcides Augusto Salzedas-Netto
Journal:  Arq Bras Cir Dig       Date:  2016 Nov-Dec

5.  Thoracoscopic Treatment of Pneumothorax in Marfan Syndrome: Hemostatic Patch to Support Lung Resection Recovery.

Authors:  Gloria Pelizzo; Eloisa Arbustini; Noemi Pasqua; Patrizia Morbini; Valeria Calcaterra
Journal:  Case Rep Surg       Date:  2018-09-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.